Literature DB >> 29971674

Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer.

Neelam Mukherjee1, Robert Svatek2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29971674      PMCID： PMC6093201          DOI： 10.1245/s10434-018-6610-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  18 in total

1.  PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.

Authors:  Jennifer H Yearley; Christopher Gibson; Ni Yu; Christina Moon; Erin Murphy; Jonathan Juco; Jared Lunceford; Jonathan Cheng; Laura Q M Chow; Tanguy Y Seiwert; Masahisa Handa; Joanne E Tomassini; Terrill McClanahan
Journal:  Clin Cancer Res       Date:  2017-06-15       Impact factor: 12.531

2.  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Authors:  Enfu Hui; Jeanne Cheung; Jing Zhu; Xiaolei Su; Marcus J Taylor; Heidi A Wallweber; Dibyendu K Sasmal; Jun Huang; Jeong M Kim; Ira Mellman; Ronald D Vale
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

3.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

Authors:  H Nishimura; M Nose; H Hiai; N Minato; T Honjo
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

4.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Authors:  Christophe Massard; Michael S Gordon; Sunil Sharma; Saeed Rafii; Zev A Wainberg; Jason Luke; Tyler J Curiel; Gerardo Colon-Otero; Omid Hamid; Rachel E Sanborn; Peter H O'Donnell; Alexandra Drakaki; Winston Tan; John F Kurland; Marlon C Rebelatto; Xiaoping Jin; John A Blake-Haskins; Ashok Gupta; Neil H Segal
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

5.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

6.  PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

Authors:  Brant A Inman; Thomas J Sebo; Xavier Frigola; Haidong Dong; Eric J Bergstralh; Igor Frank; Yves Fradet; Louis Lacombe; Eugene D Kwon
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

7.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

8.  Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.

Authors:  Ashish M Kamat; Seth Lerner; Peter Black; Joaquim Bellmunt; Colin Dinney; Noah M Hahn; Michael O'Donnell; Diane Z Quale
Journal:  Bladder Cancer       Date:  2017-07-27

9.  PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.

Authors:  Yayi He; Leslie Rozeboom; Christopher J Rivard; Kim Ellison; Rafał Dziadziuszko; Hui Yu; Caicun Zhou; Fred R Hirsch
Journal:  Med Sci Monit       Date:  2017-03-09

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.